Does Jardiance Cause Weight Loss? Honest Evidence Review

Yes — Jardiance (empagliflozin) causes modest weight loss, about 2-3 kg on average, as a side effect of how the drug works in the kidney. But the magnitude is roughly 5-10× smaller than what semaglutide (Wegovy, Ozempic) or tirzepatide (Zepbound, Mounjaro) produce, and Jardiance is not FDA-approved for weight loss. Its approved indications are type 2 diabetes glycemic control (2014), cardiovascular risk reduction in T2D plus established cardiovascular disease (2016, based on EMPA-REG OUTCOME^[1]), heart failure with reduced ejection fraction (2021, based on EMPEROR-Reduced^[2]), heart failure with preserved ejection fraction (February 2022, based on EMPEROR-Preserved^[3]), and chronic kidney disease (2023, based on EMPA-KIDNEY^[4]). The mechanism is glucosuria: blocking the SGLT2 cotransporter in the proximal renal tubule causes the kidneys to excrete roughly 70-80 g of glucose per day in the urine, a caloric loss of ~280 kcal/day. Over months that translates into 2-3 kg of weight loss that plateaus by about 6 months because the body partially compensates with increased hunger. The Cheong 2022 meta-analysis of 116 SGLT2 randomized trials^[7] confirms the magnitude across the class. If your goal is weight loss alone, Jardiance is the wrong tool. If your goal is glycemic control, heart-failure protection, or kidney protection — with modest weight loss as a welcome side effect — Jardiance is an evidence-anchored choice. Here is the verified evidence.

The honest summary

• Weight loss magnitude: approximately 2-3 kg placebo-adjusted across the major empagliflozin trials. The Cheong 2022 meta-analysis of 116 SGLT2 RCTs^[7] pooled a class-wide weight reduction in the same range. The Ridderstråle 2014 104-week empagliflozin-vs-glimepiride head-to-head^[5] recorded a net body-weight difference of approximately 4.8 kg (empagliflozin lost weight, glimepiride patients gained).
• Mechanism: Jardiance blocks SGLT2 in the proximal renal tubule, causing the kidneys to excrete ~70-80 g of glucose per day in urine. That is a caloric loss of roughly 280 kcal/day — theoretically ~1 kg of fat per month if nothing else changed. In practice, the body compensates by increasing food intake, so realized weight loss is smaller (~1-3 kg in 12-24 weeks).
• Plateau: weight loss on Jardiance plateaus by approximately 6 months. After that, weight remains stable rather than progressively decreasing. The Cheong 2022 meta-analysis^[7] documented this plateau across long-duration trials.
• FDA-approved indications: T2D glycemic control (2014), CV risk reduction in T2D + established CVD (2016, EMPA-REG OUTCOME^[1]), HFrEF (2021, EMPEROR-Reduced^[2]), HFpEF (Feb 2022, EMPEROR-Preserved^[3]), CKD (2023, EMPA-KIDNEY^[4]). Obesity is not on this list.
• Magnitude vs GLP-1s: Wegovy STEP-1 reported −14.9% body weight at 68 weeks^[8]; Zepbound SURMOUNT-1 reported −20.9% at 72 weeks^[9]. For a 100-kg starting weight that is −15 kg and −21 kg respectively. Jardiance at 2-3 kg is in a different category.
• Side effects: genital mycotic infections (3-5× baseline rate, more common in women), urinary tract infections, volume depletion/dehydration, rare euglycemic diabetic ketoacidosis (FDA Drug Safety Communication 2015), very rare Fournier's gangrene (FDA boxed warning 2018).
• Cost: retail cash price approximately $600-700/month in the US as of 2026; no generic available. Most commercial insurance and Medicare Part D cover Jardiance with a copay for the on-label indications. Self-pay GLP-1 options like orforglipron/Foundayo through LillyDirect ($149/month) are now competitive on access.
• Bottom line: Jardiance causes real but modest weight loss as a side effect. It is a good drug — for T2D, heart failure, or CKD. It is the wrong drug if your goal is weight loss alone. The GLP-1s do that job at an order of magnitude greater effect.

What is Jardiance?

Jardiance is the brand name for empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor manufactured by Boehringer Ingelheim and co-marketed with Eli Lilly. The drug is taken as a once-daily oral tablet at 10 mg or 25 mg. It was first approved by the FDA in August 2014 for glycemic control in adults with type 2 diabetes. Since then, the indication list has expanded substantially based on a succession of large outcomes trials:

• August 2014: initial FDA approval for type 2 diabetes (glycemic control, as monotherapy or as add-on to metformin, sulfonylureas, pioglitazone, or insulin).
• December 2016: reduce risk of cardiovascular death in adults with T2D and established cardiovascular disease, based on the EMPA-REG OUTCOME trial^[1]. This was the first time any glucose-lowering drug earned a CV mortality indication in a dedicated outcomes trial.
• August 2021: reduce the risk of CV death and hospitalization for heart failure in adults with heart failure with reduced ejection fraction (HFrEF), with or without diabetes — based on EMPEROR-Reduced^[2].
• February 2022: reduce the risk of CV death and hospitalization for heart failure in adults with heart failure with preserved ejection fraction (HFpEF), with or without diabetes — based on EMPEROR-Preserved^[3]. This made empagliflozin the first drug ever approved across the full ejection-fraction range of heart failure.
• September 2023: reduce the risk of sustained eGFR decline, end-stage kidney disease, CV death, and hospitalization in adults with chronic kidney disease at risk of progression, with or without diabetes — based on EMPA-KIDNEY^[4].

Conspicuously absent from that list: obesity, overweight, chronic weight management, weight loss. The FDA has never approved Jardiance for weight loss as a primary or co-primary indication. The weight loss that occurs on Jardiance is a documented side effect of the mechanism, not a therapeutic goal of the drug.

For the broader landscape of approved obesity pharmacotherapy — the GLP-1s, the combination products, and the older non-GLP-1 options — see our full GLP-1 medication reference, which has an entire section explaining why SGLT2 inhibitors like Jardiance are not GLP-1 medications and are a different drug class entirely. For the head-to-head map between the two classes, see our SGLT2-vs-GLP-1 deep-dive.

How Jardiance causes weight loss — the SGLT2 mechanism

The SGLT2 cotransporter sits in the proximal convoluted tubule of the kidney. Its job is to reabsorb glucose from the glomerular filtrate back into the bloodstream. In a person without diabetes, roughly 180 g of glucose is filtered per day, and nearly all of it is reabsorbed by SGLT2 (~90%) and SGLT1 (~10%). When SGLT2 is blocked pharmacologically by empagliflozin or another SGLT2 inhibitor, that reabsorption fails, and the unreabsorbed glucose ends up in the urine. In patients with type 2 diabetes (who typically have elevated blood glucose and therefore filter more glucose), Jardiance causes the kidneys to excrete approximately 70-80 g of glucose per day in urine.

Glucose has a caloric density of approximately 4 kcal/g. So a daily glucose loss of ~70-80 g represents a caloric loss of approximately 280-320 kcal/day. In a first-order energy-balance calculation, that is roughly 8,000 kcal/month, which corresponds to about 1 kg of body fat (since body fat is approximately 7,700 kcal/kg). Over a year, naïvely, that would predict ~12 kg of weight loss.

The actual observed weight loss on Jardiance is substantially smaller — about 2-3 kg, plateauing by 6 months. Why the gap between the theoretical caloric loss and the observed weight loss? The body compensates. Multiple mechanistic studies have documented that SGLT2 inhibition triggers a compensatory increase in food intake (hyperphagia), partly mediated by central appetite-regulating circuits that detect the glucose loss as a signal of energy deficiency. People on SGLT2 inhibitors eat modestly more, and the realized caloric deficit is much smaller than the urinary glucose loss alone would predict.

This compensatory hyperphagia is precisely the problem that GLP-1 receptor agonists solve. The GLP-1 class works centrally to reduce appetite while producing much smaller peripheral caloric losses. The net energy deficit on a GLP-1 is therefore much larger than the net energy deficit on an SGLT2 inhibitor, even though the peripheral mechanisms are completely different.

How much weight loss in the empagliflozin trials

The published empagliflozin trial program is large and consistent on the weight-loss question. Selected key data:

EMPA-REG OUTCOME (Zinman 2015 NEJM, n=7,020)^[1]. The pivotal cardiovascular outcomes trial in T2D + established CVD. Primary endpoint was 3-point MACE (HR 0.86, 95% CI 0.74-0.99, p=0.04). Weight loss was a secondary endpoint. Mean placebo-adjusted weight reduction was approximately 2.0 kg at 12 weeks and sustained through the median 3.1-year follow-up. Cardiovascular mortality was reduced by 38%, all-cause mortality by 32%, and heart- failure hospitalization by 35%.

Ridderstråle 2014 (Lancet Diabetes Endocrinol, n=1,549, 104 weeks)^[5]. This was the longest direct head-to-head trial of empagliflozin against an active comparator: empagliflozin 25 mg vs glimepiride (a sulfonylurea), both added to metformin, in T2D patients with inadequately controlled A1c on metformin alone. The body- weight result is the cleanest in the empagliflozin literature because it captures both directions: empagliflozin patients lost approximately 3.2 kg from baseline; glimepiride patients gained approximately 1.6 kg. Net between- group difference: approximately 4.8 kg. This is the trial most often cited when comparing empagliflozin to weight-gaining T2D therapies (sulfonylureas, insulin, thiazolidinediones).

Kovacs 2014 (Diabetes Obes Metab, n=498, 24 weeks)^[6]. Empagliflozin 10 mg or 25 mg added to pioglitazone (with or without metformin) in T2D patients. Weight reduction with empagliflozin was approximately 1.6-2.0 kg vs essentially no change with placebo. This trial helped establish that the empagliflozin weight effect is preserved even when used in combination with pioglitazone, which itself tends to cause weight gain through fluid retention and adipogenesis.

EMPEROR-Reduced (Packer 2020 NEJM, n=3,730)^[2]. Empagliflozin vs placebo in HFrEF (with or without diabetes). Primary composite of CV death or hospitalization for HF was reduced. Weight loss was modest and consistent with the T2D trials, in the 1-2 kg range over median follow-up.

EMPEROR-Preserved (Anker 2021 NEJM, n=5,988)^[3]. Empagliflozin vs placebo in HFpEF (with or without diabetes). Primary composite hazard ratio 0.79 (95% CI 0.69-0.90, p<0.001). This was the first drug ever to show clear benefit in HFpEF, where nothing else had worked. Weight loss again modest and similar in magnitude to the other empagliflozin trials.

EMPA-KIDNEY (Herrington 2023 NEJM, n=6,609)^[4]. Empagliflozin vs placebo in adults with CKD at risk of progression (with or without diabetes). Primary composite of kidney disease progression or CV death was reduced (HR 0.72). Weight effects again in the same 2-3 kg range.

Cheong 2022 (Obesity, meta-analysis of 116 RCTs)^[7]. The largest pooled analysis of SGLT2 inhibitors and weight. Across the class (empagliflozin, dapagliflozin, canagliflozin, ertugliflozin), the pooled placebo-adjusted weight reduction was approximately 2 kg, with a consistent class effect and a clear plateau by ~6 months. The Cheong meta-analysis is the canonical citation for the magnitude question: SGLT2 inhibitors as a class produce ~2 kg of weight loss; empagliflozin is not exceptional within the class.

Taken together, the empagliflozin trial program supports a clear, narrow conclusion: Jardiance produces approximately 2-3 kg of weight loss in adults with T2D or with HF or with CKD, sustained for the duration of the trials but plateauing at roughly 6 months. The effect is real, reproducible, and modest.

Why weight loss plateaus on Jardiance

The plateau effect is one of the most clinically important features of SGLT2 inhibitor weight loss. Patients often start Jardiance, lose a few pounds in the first 2-3 months, and then find that the scale stops moving even though they are still taking the drug and the drug is still doing its job. They sometimes interpret the plateau as a sign that the drug has “stopped working,” which is not what is happening.

What is happening: the urinary glucose excretion continues at the same rate as long as the patient is taking the drug, but compensatory hyperphagia matches the caloric loss. In thermodynamic terms, energy in goes up by approximately the same amount that energy out (via urine glucose) goes up, and the net energy balance returns to neutral. Body weight stabilizes at a new, slightly lower setpoint.

Several mechanistic studies have characterized this. The compensatory hunger is partly mediated through central appetite-regulating circuits that sense the chronic glucose loss as an energy deficiency signal, and partly through increases in counter-regulatory hormones (glucagon, growth hormone). The end result is that the realized caloric deficit on long-term SGLT2 therapy is much smaller than the urinary glucose loss alone would predict.

Clinically, this means three things for patients:

• The Jardiance weight loss is front-loaded. Most of it happens in the first 12-24 weeks. After that, the scale stabilizes.
• Combining Jardiance with caloric restriction or with a GLP-1 can produce more weight loss than Jardiance alone, because the GLP-1 suppresses the compensatory hyperphagia.
• Stopping Jardiance after the weight loss has been achieved typically causes regain of most or all of the lost weight, because the urinary glucose excretion stops and the compensatory eating pattern persists.

Jardiance vs GLP-1s for weight loss — the magnitude gap

For people whose primary goal is weight loss, the most important comparison is between Jardiance and the FDA-approved obesity medications. The published trial results put the two classes in completely different magnitude categories:

• Jardiance (empagliflozin): approximately 2-3 kg placebo-adjusted across pivotal trials. As a percentage of starting body weight (typical baseline ~85-90 kg in trial populations), that is approximately 2-3%.
• Wegovy (semaglutide 2.4 mg weekly): STEP-1 reported −14.9% body weight at 68 weeks in adults with overweight or obesity without diabetes^[8]. For a 100-kg starting weight, that is approximately −15 kg.
• Zepbound (tirzepatide 15 mg weekly): SURMOUNT-1 reported −20.9% body weight at 72 weeks^[9]. For a 100-kg starting weight, that is approximately −21 kg.
• Ozempic (semaglutide 1-2 mg weekly, T2D indication): approximately 4-6 kg over 30 weeks at full dose, smaller than Wegovy because the dose is lower.
• Mounjaro (tirzepatide 5-15 mg weekly, T2D indication): approximately 6-12 kg over 40 weeks depending on dose, in T2D patients.

On a head-to-head magnitude basis, Wegovy produces roughly 5-7× more weight loss than Jardiance, and Zepbound produces roughly 7-10× more. There is no realistic dose or duration of Jardiance that closes this gap. The class effect of SGLT2 inhibitors caps out at approximately the level captured in the Cheong 2022 meta-analysis^[7]: ~2 kg, plateauing by 6 months.

For T2D patients with both obesity and cardiovascular or kidney risk, the answer is increasingly both — combine an SGLT2 inhibitor (for cardio-renal protection) with a GLP-1 (for substantial weight loss and additional cardiovascular benefit). The ADA 2025 Standards of Care recommend this combination for patients with established ASCVD, heart failure, or CKD whose A1c is more than 1.5-2.0 percentage points above goal. See our SGLT2-vs-GLP-1 deep-dive for the combination evidence base.

For lean-mass preservation context, GLP-1-driven weight loss is a mix of fat mass and lean mass, and pairing the medication with resistance training plus adequate protein is essential. SGLT2-driven weight loss is also mixed but the absolute amount of lean mass at stake is much smaller because the absolute weight loss is much smaller. See our creatine and lean-mass preservation article and our best protein powder for weight loss on a GLP-1 review for the protein-and-resistance-training pattern that applies primarily to GLP-1 patients.

Side effects and safety

The empagliflozin safety profile is broadly favorable and well- characterized after a decade on market. The most common and most clinically important adverse events:

• Genital mycotic infections (yeast infections): the most common SGLT2 side effect, occurring in approximately 5-10% of patients (vs 1-2% on placebo). Women are affected roughly 2-3× more often than men. Usually responds to topical antifungals; recurrent cases may need switching off the SGLT2 class.
• Urinary tract infections: modestly increased incidence (~3-5% vs ~2% on placebo). Severe UTIs and pyelonephritis are rare but real.
• Volume depletion and dehydration: the SGLT2- driven osmotic diuresis can cause hypotension, dizziness, and dehydration, especially in elderly patients and those on loop diuretics. Dose reductions of concomitant diuretics are often recommended at initiation.
• Euglycemic diabetic ketoacidosis (DKA): rare but serious. The FDA issued a Drug Safety Communication in May 2015 highlighting cases of DKA at normal or near-normal blood glucose levels in SGLT2 users. Risk factors include insulin dose reductions, low-carbohydrate or ketogenic diets, severe illness, dehydration, surgery, alcohol use. Patients should be educated to stop the drug and seek care if they develop nausea, vomiting, abdominal pain, or rapid breathing.
• Fournier's gangrene: a very rare but serious necrotizing fasciitis of the perineum. The FDA added a boxed warning to the SGLT2 class in August 2018 based on 12 postmarketing cases. Postmarketing reports remain very rare, but the severity is high.
• Acute kidney injury: early concerns about AKI on SGLT2 initiation have largely been allayed by the DAPA-CKD, EMPA-KIDNEY, and CREDENCE trials, which all showed long-term kidney protection. Transient eGFR dips on initiation are common but reverse with continued use.
• Bone fracture and amputation: the canagliflozin CANVAS trial reported a doubled amputation rate; this signal has not been replicated in the empagliflozin trials and is generally treated as canagliflozin-specific.
• Hypoglycemia: low risk with Jardiance monotherapy because the mechanism is glucose-dependent (urine glucose excretion only happens when blood glucose is above the renal threshold). Hypoglycemia risk increases when Jardiance is added to insulin or sulfonylureas; dose reductions of those agents are commonly needed.

Contraindications: type 1 diabetes (DKA risk), severe renal impairment below the eGFR thresholds in the prescribing information, history of recurrent severe genital infections, prior Fournier's gangrene. Pregnancy is not a formal contraindication but the drug is generally avoided in pregnancy due to limited data.

Should you use Jardiance for weight loss?

The honest answer is no, with carefully defined exceptions:

• If your primary goal is weight loss and you do not have T2D, HFrEF, HFpEF, or CKD: Jardiance is the wrong tool. The magnitude is too small (2-3 kg) and the drug is not FDA-approved for this indication. The right tools are the FDA-approved obesity medications — semaglutide (Wegovy), tirzepatide (Zepbound), or the older options (phentermine-topiramate / Qsymia, naltrexone-bupropion / Contrave, liraglutide / Saxenda, orlistat). See our full GLP-1 reference for the landscape.
• If you have T2D and you want both glycemic control and modest weight loss: Jardiance is a reasonable first-line or second-line choice (per ADA 2025 Standards of Care). The 2-3 kg of weight loss is a useful side effect; the A1c reduction of ~0.5-0.8% is the primary indication. If you also have established CVD, HF, or CKD, the cardio-renal indications make the case even stronger.
• If you have HFrEF or HFpEF (with or without diabetes): Jardiance has a clear cardiovascular indication independent of weight or A1c. Use it for the heart-failure benefit; the modest weight loss is a bonus.
• If you have CKD at risk of progression: Jardiance has a clear kidney indication (EMPA-KIDNEY^[4]) and the renal-protective effect is the dominant reason to prescribe it. The weight loss is, again, a side benefit.
• If you have T2D + obesity + ASCVD/HF/CKD: the increasingly recommended approach is combination therapy: Jardiance (or another SGLT2) for cardio-renal protection, plus a GLP-1 (semaglutide, tirzepatide) for substantial weight loss and additional cardiovascular benefit. The two classes have non-overlapping mechanisms and are commonly combined in real-world T2D management.

Beyond these scenarios, the off-label use of Jardiance for weight loss alone is not supported by the evidence base. The weight effect is too small relative to the FDA-approved obesity medications, the side-effect profile (yeast infections, UTIs, rare DKA) is not zero, and the financial cost (~$600/month at retail) is not trivial. Patients considering Jardiance for weight loss alone should reconsider and look at the GLP-1 class instead.

How Jardiance fits in our coverage

Jardiance sits at the edge of our coverage scope. We focus primarily on weight-loss pharmacotherapy — the GLP-1 receptor agonists and the older obesity medications — because that is where the strongest evidence base for clinically meaningful weight loss is. Jardiance and the SGLT2 class come into our coverage because patients frequently ask about them as weight-loss options. The short answer: they produce real but modest weight loss; they are not first-line for weight loss alone; they are a strong choice when the primary indication is T2D, heart failure, or kidney disease.

Related research and tools:

• How rapid is weight loss with Farxiga? Honest evidence review — the sister-drug article on dapagliflozin. Same glucosuria mechanism, same ~1-3 kg magnitude, same 6-month plateau, same “not FDA-approved for weight loss” verdict
• SGLT2 inhibitors vs GLP-1s: Jardiance, Farxiga, and the head-to-head map — the parent comparison hub covering all three major SGLT2 inhibitors against the GLP-1 class
• Full GLP-1 medication reference — the comprehensive list of GLP-1 receptor agonists, with the “SGLT2 inhibitors are NOT GLP-1 RAs” section explaining the class distinction
• Mounjaro vs Zepbound: same drug, different brands — the tirzepatide article. Tirzepatide produces ~21% body weight loss vs Jardiance ~2-3%
• Semaglutide drug page — the GLP-1 we compare Jardiance against most often
• Tirzepatide drug page — the dual GIP/GLP-1 agonist with the largest weight- loss magnitude in published trials
• Best protein powder for weight loss on a GLP-1 — protein adequacy for lean-mass preservation during medication-driven weight loss. More relevant to GLP-1 patients than to Jardiance patients because the absolute weight loss is much larger
• GLP-1 + creatine + resistance training for lean-mass preservation — the muscle-preservation protocol for substantial medication-driven weight loss
• Is sushi good for weight loss? The honest evidence review — the parallel evidence walkthrough for the popular- food category
• Does watermelon cause weight loss? The honest evidence review — another niche evidence-grade article in the same editorial pattern

Bottom line

• Yes, Jardiance (empagliflozin) causes weight loss — approximately 2-3 kg, on average, in pivotal trials. The mechanism is urinary glucose excretion (~70-80 g glucose/day, ~280 kcal/day caloric loss), partially offset by compensatory hyperphagia.
• The weight effect plateaus by approximately 6 months. After that, weight remains stable but does not progressively decline.
• Jardiance is not FDA-approved for weight loss. Its FDA-approved indications are T2D glycemic control (2014), CV risk reduction in T2D + CVD (2016), HFrEF (2021), HFpEF (2022), and CKD (2023). The cardiovascular and kidney benefits are the dominant reasons to prescribe Jardiance.
• Magnitude vs GLP-1s: Wegovy STEP-1 produced −14.9% body weight at 68 weeks^[8]; Zepbound SURMOUNT-1 produced −20.9% at 72 weeks^[9]. Jardiance at 2-3 kg is in a different category — roughly 5-10× smaller.
• For patients with T2D plus obesity plus cardio-renal risk, combination SGLT2 + GLP-1 is increasingly the standard of care per ADA 2025. Use Jardiance for the cardio-renal benefit; use the GLP-1 for the substantial weight loss.
• Side effects: genital mycotic infections (most common), UTIs, volume depletion, rare euglycemic DKA, very rare Fournier's gangrene. Generally favorable safety after a decade on market.
• If your primary goal is weight loss and you do not have T2D, HF, or CKD, Jardiance is the wrong tool. The FDA-approved obesity medications are the right tools.

Important disclaimer. This article is educational and does not constitute medical advice. Decisions about whether to start, continue, or stop Jardiance (empagliflozin) should be made with your prescribing clinician, who can weigh your specific T2D status, cardiac and renal function, concomitant medications (especially insulin, sulfonylureas, and diuretics), pregnancy plans, and risk factors for euglycemic DKA or genital infections. Patients with type 1 diabetes should not take SGLT2 inhibitors outside of specific monitored protocols due to DKA risk. Patients on low-carbohydrate or ketogenic diets, those undergoing surgery, and those with acute illness should discuss SGLT2 dose-holds with their clinician. Every primary source cited here was independently verified against PubMed E-utilities on 2026-05-16. Specific hazard ratios, confidence intervals, and weight-loss magnitudes cited are from published abstracts and primary publications; full-text endpoints may differ slightly and should be confirmed against the trial publication for any critical clinical decision.

Last verified: 2026-05-16. Next review: every 12 months, or sooner if a major new SGLT2 outcomes trial publishes or if Jardiance receives a new FDA indication.